Data you can trust
GLP‑accredited bioanalysis and rigorously controlled in vivo and in vitro studies designed with regulatory expectations in mind.
About Us
Transforming preclinical research into confident decision‑making
Pharmidex is a UK‑based contract research organisation supporting biotech, pharmaceutical, and academic partners with high‑quality preclinical and bioanalytical research. We generate robust, regulator‑ready data that enables confident decisions from early discovery through IND‑ and CTA‑enabling stages.
Our teams combine scientific depth, regulatory experience, and operational pragmatism to deliver studies that are not only technically sound, but genuinely useful for progressing development programmes.
Why Pharmidex
Developing new medicines is complex, high‑risk, and time‑critical. Our role is to reduce uncertainty and friction at every stage of preclinical development. What our partners value most:
Integrated capability
In‑life, formulation, bioanalysis, and translational insight delivered under one roof, reducing hand‑offs and timelines.
Scientific partnership, not just execution
Senior scientists actively involved in study design, interpretation, and problem‑solving.
Flexible and responsive delivery
Programmes tailored to your compound, modality, and development stage rather than rigid templates.
Who We Work With
We support a broad range of organisations across the life sciences ecosystem:
- Early‑stage and venture‑backed biotech companies
- Mid‑size and large pharmaceutical organisations
- Academic groups and translational research consortia
- Grant‑funded and public–private partnerships
Whether you need a focused standalone study or a fully integrated preclinical package, we adapt our approach to fit your objectives, timelines, and regulatory pathway.
Our collaborations are built on clarity, transparency, and shared ownership of outcomes.
- Collaborative study design
Early scientific input to align studies with development goals
- Clear communication
Regular updates, direct access to scientists, and no hidden assumptions
- Single‑point project leadership
Streamlined delivery and accountability
- Actionable reporting
Data presented in a way that supports real decisions, not just documentation
Rather than offering disconnected services, we design studies around the questions that matter most to programme progression.
- Preclinical Pharmacology & In Vivo Studies
Generate high‑quality efficacy and mechanistic data to support candidate selection and translational confidence.
- Bioanalysis (GLP and non‑GLP)
Accurate, validated quantitative bioanalysis to support PK, ADME, toxicokinetic, and clinical‑stage decision making.
- Toxicology & Safety Support
Well‑designed safety and tolerability studies to inform IND/CTA submissions and risk assessment.
- Translational & Discovery Support
Integrated approaches that link exposure, biology, and outcome to strengthen go/no‑go decisions.
Since our founding in 2002, Pharmidex has grown into a trusted preclinical partner with a strong delivery record.
- 17,000+ studies completed
- 400+ global clients supported
- 30+ successful collaborative research and grant programmes
Our experience spans a wide range of therapeutic areas, modalities, and development challenges.
If you are looking for a preclinical partner who combines regulatory rigour with scientific insight and flexibility, we would welcome a discussion.
Our collaborations are built on clarity, transparency, and shared ownership of outcomes.
- Collaborative study design
Early scientific input to align studies with development goals
- Clear communication
Regular updates, direct access to scientists, and no hidden assumptions
- Single‑point project leadership
Streamlined delivery and accountability
- Actionable reporting
Data presented in a way that supports real decisions, not just documentation
Our infrastructure is designed to support both flexibility and compliance, enabling efficient delivery without compromising standards.
Pharmidex is led by senior scientists and industry professionals with decades of experience across pharmaceutical R&D, CRO environments, and academic research.
This depth of expertise ensures that scientific judgement, not just process, guides every programme we deliver.
Company highlights
17000+
Single site studies conducted to date
300+
Pharmaceuticals, biotechnology, virtual, academia & medical charities customers in 24 countries
12
Worked with Pharma companies of the top 25 Blue Chip
23
Years in industry
